RxDoctor Payments Data

Josh George, MD

Gastroenterology · Fort Worth, TXNPI 1558375634

Payments from drug & device makers

$9,153in general payments, 2019–2025

Across 487 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Ambu Inc.$903
  • Johnson & Johnson$822
  • Takeda Pharmaceuticals U.S.A., Inc.$789
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$591
  • Boston Scientific$341
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$9,02399%
  • Education$1301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,153 in reported general payments places this provider in the 70th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$192,745
Medicare patients
529
Services billed
3,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$325,718
CreonLipase/Protease/Amylase46$119,369
LinzessLinaclotide53$40,289
ClenpiqSod Picosulf/Mag Ox/Citric Ac151$26,031
Dexlansoprazole DrDexlansoprazole43$13,012
Mesalamine36$8,630
TrulancePlecanatide12$8,093
MovantikNaloxegol Oxalate14$6,773
SutabSod Sulf/Pot Chloride/Mag Sulf41$6,731
Sucralfate54$5,027
Ursodiol60$4,275
Omeprazole218$3,460
Dicyclomine Hcl107$3,102
Lansoprazole16$2,221
Pantoprazole Sodium145$2,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$822$325,71812 claims
AbbVieCreon, Linzess$2,862$159,65899 claims
Ferring Pharmaceuticals Inc.Clenpiq$100$26,031151 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$591$8,09312 claims
Redhill Biopharma Inc.Movantik$93$6,77314 claims
Braintree Laboratories, Inc.Sutab$52$6,73141 claims
SandozLansoprazole$13$2,22116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →